The nanoparticles improved the circulation half-life compared to free DFO, facilitated uptake of the drugs by tumor cells and once released DFO and YC1 exerted a synergistic anti-tumor effect in both subcutaneous and orthotopic pancreatic cancer xenografts. The gene discussed is RBMS1; the disease is pancreatic neoplasm.